Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cells

被引：0
|
作者：
I Tsaur
J Makarević
E Juengel
M Gasser
A-M Waaga-Gasser
M Kurosch
M Reiter
S Wedel
G Bartsch
A Haferkamp
C Wiesner
R A Blaheta
机构：
[1] Goethe-University,Department of Urology
[2] University of Wuerzburg,Department of Surgery I
来源：
British Journal of Cancer | 2012年 / 107卷
关键词：
prostate cancer; RAD001 resistance; integrins; Akt; migration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：847 / 855
页数：8
相关论文
共 5 条
  • [1] Resistance to the mTOR-inhibitor RAD001 elevates integrin α2-and β1-triggered motility, migration and invasion of prostate cancer cells
    Tsaur, I.
    Makarevic, J.
    Juengel, E.
    Gasser, M.
    Waaga-Gasser, A-M
    Kurosch, M.
    Reiter, M.
    Wedel, S.
    Bartsch, G.
    Haferkamp, A.
    Wiesner, C.
    Blaheta, R. A.
    BRITISH JOURNAL OF CANCER, 2012, 107 (05) : 847 - 855
  • [2] IN VITRO STUDIES ON RESISTANCE MECHANISM IN PROSTATE CARCINOMA CELLS INDUCED BY THE MTOR INHIBITOR RAD001
    Tsaur, I
    Wedel, S. A.
    Makarevic, J.
    Bartsch, G.
    Haferkamp, A.
    Blaheta, R.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 294 - 294
  • [3] OVERCOMING RAD001 TRIGGERED RESISTANCE IN PROSTATE CANCER: CDK1-CYCLIN B COMPLEX
    Tsaur, Igor
    Makarevic, Jasmina
    Reiter, Michael
    Kurosch, Martin
    Bartsch, Georg
    Wiesner, Christoph
    Wedel, Steffen
    Haferkamp, Axel
    Blaheta, Roman
    JOURNAL OF UROLOGY, 2012, 187 (04): : E320 - E321
  • [4] p21 WAF1/Cip1-mediated radiosensitization of bladder cancer cells by mTOR inhibitor, RAD001 disrupts the balance between autophagy and apoptosis
    Mansure, Jose J.
    Solanki, Shraddha
    Alamjed, Wael
    Nassim, Roland
    Cury, Fabio
    Chevalier, Simone
    Kassouf, Wassim
    CANCER RESEARCH, 2016, 76
  • [5] BOLERO: An international phase III trial program for the treatment of HER2/neo-positive (BOLERO 1/3) and ER-positive (BOLERO 2) metastatic breast cancer with the mTOR inhibitor RAD001 (Everolimus)
    Jonat, W.
    Eiermann, W.
    Janni, W.
    Rody, A.
    Muth, M.
    ONKOLOGIE, 2010, 33 : 22 - 22
1